The future of RIP2/RICK/CARDIAK as a biomarker of the inflammatory response to infection.
Biological markers of disease have become increasingly important for the clinician to diagnose, predict and monitor progression, and assess the therapeutic effect of interventions on underlying pathogenic mechanisms. Robust and specific biomarkers would be very useful in inflammation, where they may facilitate early identification of tissue injury, predict disease progression and help to modify disease outcomes. However, at present, there are no robust biomarkers to predict the course of inflammation. Here, we discuss emerging data indicating that RIP2, a putative serine/threonine protein kinase, may serve as a biomarker for the resolution of peritoneal dialysis-associated peritonitis and, more generally, of the acute inflammatory response to infection.
McCully
Michelle L
ML
Departments of Microbiology & Immunology & Medicine, The FOCIS Centre for Clinical Immunology & Immunotherapeutics, Robarts Research Institute, The University of Western Ontario, Ontario, Canada N6A 5K8. mmccully@robarts.ca
Fairhead
Todd
T
Blake
Peter G
PG
Madrenas
Joaquín
J
D015415:Biomarkers / Q000378:metabolism; D006801:Humans; D007239:Infections / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism*; D007249:Inflammation / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism; D010530:Peritoneal Dialysis / Q000009:adverse effects; D010538:Peritonitis / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism*; D053475:Receptor-Interacting Protein Serine-Threonine Kinase 2 / Q000096:biosynthesis*
D015415:Biomarkers; C506253:RIPK2 protein, human; D053475:Receptor-Interacting Protein Serine-Threonine Kinase 2